Rahul Khara Sells 1,649 Shares of Disc Medicine (NASDAQ:IRON) Stock

Posted by Brenda Bartman on Jul 2nd, 2026

Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) insider Rahul Khara sold 1,649 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $123,675.00. Following the completion of the sale, the insider owned 52,173 shares in the company, valued at approximately $3,912,975. This represents a 3.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Rahul Khara also recently made the following trade(s):

On Friday, June 26th, Rahul Khara sold 851 shares of Disc Medicine stock. The stock was sold at an average price of $75.00, for a total value of $63,825.00.
On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The stock was sold at an average price of $70.22, for a total value of $526,650.00.

Disc Medicine Stock Up 2.5%

Disc Medicine stock opened at $74.95 on Thursday. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The firm has a market capitalization of $2.86 billion, a price-to-earnings ratio of -11.32 and a beta of 0.97. The stock’s fifty day moving average is $69.08 and its two-hundred day moving average is $70.50. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.00 and a current ratio of 24.00.

Disc Medicine (NASDAQ:IRON – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). Analysts predict that Disc Medicine, Inc. will post -6.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Disc Medicine by 22.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock worth $756,000 after purchasing an additional 2,807 shares during the period. Millennium Management LLC lifted its position in Disc Medicine by 1,277.1% during the first quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock valued at $5,386,000 after buying an additional 100,620 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Disc Medicine by 3.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock worth $4,793,000 after buying an additional 3,454 shares during the period. Legal & General Group Plc increased its position in shares of Disc Medicine by 18.0% in the second quarter. Legal & General Group Plc now owns 24,097 shares of the company’s stock worth $1,276,000 after acquiring an additional 3,682 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Disc Medicine by 21.6% in the 2nd quarter. Invesco Ltd. now owns 16,817 shares of the company’s stock valued at $891,000 after acquiring an additional 2,983 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Morgan Stanley lifted their price objective on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Monday, June 15th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Wedbush reissued an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a research note on Wednesday, June 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $105.80.

Read Our Latest Report on IRON

Disc Medicine Company Profile

(Get Free Report)

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.